Product Development Plan. Subject to Section 4.3.2(i), all Development activities to be conducted during the Collaboration Period in connection with any Compound or Licensed Product will be performed by the Parties in accordance with the terms and conditions set forth in this Section 4 and the Licensed Product development plan as set forth in Exhibit A (as such plan may be amended from time to time by mutual agreement of the Parties, the “Product Development Plan”). The Product Development Plan shall include, among other things (a) all Development activities reasonably anticipated to be undertaken by each Party to advance Development activities with respect to the first Licensed Product, including the planning, design and implementation of the Phase I/II Clinical Trial, (b) all pre-clinical, Phase I/II Clinical Trial and other development activities reasonably anticipated to be required to be performed by or on behalf of Spark, (c) the reasonably anticipated technical and Manufacturing activities to be undertaken by the Parties to support the Phase I/II Clinical Trial, (d) a reasonably detailed budget for each of the activities to be performed by Spark and Pfizer under the Product Development Plan (the “Budget”) and (e) particular personnel and other resources that each Party will be required to contribute to the performance of Product Development Plan activities. The Parties agree that by consensus, the JSC may add one or more additional Product Development Plans with respect to additional Compounds and Licensed Products. For the opening of Clinical Trial sites in jurisdictions outside the United States, Pfizer shall provide an appropriate representative who will join Spark study team meetings and provide reasonable assistance and advice.
Product Development Plan. The initial Development Plan for the Product in the Field is set forth in Exhibit 1.30 (the “Initial Development Plan”). The JDC will direct, coordinate and manage the Development of the Product in the Field, according to the Development Plan. The following provisions shall apply with respect to the Development of Products:
Product Development Plan. Commencing on the date that Company exercises an Option and Consultant licenses the Licensed Rights, a product development plan (“Product Development Plan”) with estimated costs and timelines will be completed within sixty (60) days by Company for the development and commercialization of each product. Subject to the R&D Chargeback, Company agrees to solely bear the full cost and responsibility for all evaluation expenses, product development, clinical assessments, commercial preparation, patent protection and related patent expenses, consulting costs. THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
Product Development Plan. The Design & Development Program will be conducted in accordance with the Product Development Plan that describes the work to be pursued by Ambrx and Elanco during each Program Year. Except for the first Program Year, the Product Development Plan may be updated and approved by the Steering Committee at any time, but no later than sixty (60) days prior to the start of each Program Year. The Product Development Plan in effect at any time may not be amended except as agreed in writing by the Steering Committee. If at any time during the Program Year, either Party determines that a change to the Product Development Plan would benefit the Design & Development Program, such Party will prepare and submit to the Steering Committee a written proposal detailing its proposed changes to the Product Development Plan. Any proposed change to the Product Development Plan that would increase Ambrx’ scope of responsibility or require the commitment of additional resources, whether personnel or monetary, by Ambrx are subject to (a) the prior approval via Notice of the President and CEO of Ambrx; and (b) full reimbursement by Elanco. Proposed change(s) shall be submitted to the Steering Committee at least fifteen (15) days prior to its next regular meeting or communicated by means of such other notice as agreed by the Parties.
Product Development Plan. The Steering Committee will approve a detailed Product Development Plan which will be prepared by Senomyx within [***] of the selection of a Selected Compound under the applicable Phase of the Collaborative Program. The Product Development Plan, which will outline the responsibilities of the parties, will be attached as Appendix D to the Agreement, and incorporated into the Agreement by reference.
Product Development Plan. Within three (3) months after the Effective Date of this Agreement Licensee shall submit a confidential product development plan (“Plan”) to University. The Plan shall set forth Licensee’s best estimate and forecasts of the primary tasks and schedule of milestones for the identification and development of Licensed Product(s) and Licensed Services. The Plan and any updates thereto shall contain the following minimum information:
Product Development Plan. The Product Development Plan is targeted for completion of September 17, 1999
Product Development Plan. The initial Development Plan for the Product in the Field is set forth in Exhibit C (the “Initial Development Plan”). The JDC will direct, coordinate, and manage the Development of the Product in the Field, according to the Development Plan. The Development Plan for the Product will include, among other things, the indications in the Field for which the Product is to be Developed and other exploratory indications in the Field for which the Product may be developed, critical activities to be undertaken, certain timelines, go/no go decision points and relevant decision criteria and certain allocations of responsibilities between the Parties for the various activities to be undertaken under the Development Plan. During the Term, the JDC will amend the Development Plan on an ongoing basis as necessary. [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.
Product Development Plan. The Parties agree to jointly develop a plan of action and milestones to perform the Development Work (the “Product Development Plan”), which will be negotiated in good faith, duly executed by the Parties, and attached hereto as Exhibit A to this Agreement. All development activities shall be performed by Manufacturer in compliance with all applicable Laws. Manufacturer and Supplier shall use commercially reasonable efforts to complete the development of the Product in a timely fashion consistent with the Product Development Plan, and keep Company informed of the progress and status of the development activities. Upon successful completion of the Development Work, the Parties’ mutually agreed specifications for the Product (the “Specifications”) will be attached hereto as Exhibit B. Except as set forth in Section 3.4, fees for the development activities for the Product shall be as provided in the Product Development Plan. Supplier shall invoice Manufacturer, and Manufacturer shall invoice Company, for each of its completed steps of the Product Development Plan monthly. Invoices shall contain details regarding the steps completed and the amount being charged for such completed work. Payments of invoices shall be in accordance with Section 7.5(a).
Product Development Plan. Immunovaccine will develop the Product in accordance with the Product Development Plan mutually agreed between the Parties and as attached as Appendix A to this Agreement [***] [Redacted for competitive reasons.] The Product Development Plan shall include without limitation, pre-clinical studies, IND filing, a Phase I study and a Phase Ha trial. Immunovaccine shall have the right to make such adjustments to the Product Development Plan that are reasonably required and scientifically justified for scientific and/or regulatory reasons with Merck’s prior written consent, such consent not to be unreasonably withheld or delayed.
